You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

22 Items
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Neoadjuvant, Adjuvant, Palliative
Updated
Jul 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Cancer Type: Sarcoma, Soft Tissue     
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Oct 2017
Cancer Type: Endocrine, Thyroid     
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Jun 2019
Cancer Type: Genitourinary, Testis     
Intent: Curative
Apr 2016
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - For 1st line and 2nd line monotherapy treatment of BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma or metastatic disease according to specific criteria.
Jun 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
Exceptional Access Program
    Treatment of chronic lymphocytic leukemia/ small lymphocytic lymphoma according to clinical criteria
Jun 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
venetoclax (Unfunded),
riTUXimab (Unfunded)
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
Feb 2018
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Oct 2017
Cancer Type: Lung, Mesothelioma     
Intent: Palliative
May 2019